Tag: IMGN853
FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...
ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...
Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...
Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
The Phase 3 SOROYA trial demonstrated promising response rates with mirvetuximab soravtansine, previously known as IMGN853, in patients with platinum-resistant ovarian cancer and high folate receptor–alpha...
Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize...
ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in 1993, have entered into an...
AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize...
Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression...
ASCO 2020: Mirvetuximab Soravtansine + Bevacizumab Shows Encouraging Results in Recurrent...
Initial data from the FORWARD II study (NCT02606305), a phase Ib/II study evaluating mirvetuximab soravtansine (also known as IMGN853), in combination with bevacizumab (Avastin®;...
ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine
Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...
Data Highlights the Potential to Combine Mirvetuximab Soravtansine with an Immune...
Preclinical data demonstrate the potential for enhancing the activity of mirvetuximab soravtansine, also known as IMGN853, when the investigational agent is combined with and...
ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...
Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...
ImmunoGen and Merck Evaluate Mirvetuximab Soravtansine in Combination with Pembrolizumab in...
ImmunoGen and Merck, known as MSD outside the United States and Canada, have entered into a clinical research collaboration for the assessment of ImmunoGen's...
